1. < Home

transthyretin amyloid cardiomyopathy

Transthyretin Cardiac Amyloidosis in an Older Athlete

O'Brien D, Reiss RA. Transthyretin Cardiac Amyloidosis in an Older Athlete. Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. PMID: 42534173; PMCID: PMC13419844.

By afschroeder • July 31, 2026
Clinical Outcomes and Health Care Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

By afschroeder • July 16, 2026
Sex Differences in Hospitalizations in the 6 Months Before a Diagnosis of Transthyretin Amyloid Cardiomyopathy

Kwok CS, Qureshi AI, Steeds RP, Fonarow GC, Bozkurt B, Fontana M, Gillmore JD, Moody WE. Sex Differences in Hospitalizations in the 6 Months Before[...]

By afschroeder • March 30, 2026
Clinical Outcomes and Healthcare Costs in Patients Hospitalized With Heart Failure and Transthyretin Amyloid Cardiomyopathy: Findings From GWTG-HF

Shoji S, Ikeaba U, Fonarow GC, Selvaraj S, Lewsey SC, Pandey A, Khouri MG, Alhanti B, McDermott JJ, Wright J, Vaduganathan M, Greene SJ. Clinical[...]

By afschroeder • November 11, 2025
Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

Jaiswal V, Hanif M, Mashkoor Y, Jaiswal A, Prasad T, Rajak K, Khan MS, Mentz RJ, Fonarow GC. Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes[...]

By sjmartinez • January 16, 2025